- Telix Pharmaceuticals (TLX) receives approval from the US Food and Drug Administration (FDA) to begin a phase two kidney cancer therapy study
- The study will be undertaken in patients with advanced clear cell renal cell carcinoma, which is the most common and aggressive form of kidney cancer
- The study will evaluate Telix’s investigational kidney cancer therapy, TLX250
- The primary aim of this study is to determine the efficacy of combining TLX250 with immunotherapy
- Shares in Telix are up 5.18 per cent on the market and are trading at $6.91 at 10:43 am AEST
Telix Pharmaceuticals (TLX) has received approval from the US Food and Drug Administration (FDA) to begin a phase two kidney cancer therapy study.
The phase two study will be undertaken in patients with advanced clear cell renal cell carcinoma (ccRCC), which is the most common and aggressive form of kidney cancer.
Current treatment includes surgery and immunotherapy, however it depends on how much the tumour has grown.
The study will evaluate Telix’s investigational kidney cancer therapy, TLX250.
TLX250 targets carbonic anhydrase IX (CA9), a protein that is highly present in patients who demonstrate a limited response to cancer immunotherapy.
The study will evaluate TLX250-delivered radiation as an immune system primer in combination with immunotherapy Opdivo.
The primary aim of this study is to determine the efficacy of combining TLX250 with immunotherapy.
Chief Medical Officer Colin Hayward commented on the study.
“The introduction of immunotherapy agents has improved the outlook for patients with advanced clear cell renal cancer, but most patients eventually progress,” Dr Hayward said.
“This therapy, along with patient selection and treatment response assessment with our CA9-targeting imaging agent TLX250-CDx, may potentially offer a new paradigm of more accurate staging and personalised treatment for kidney cancer patients through a “theranostic” approach.”
Shares in Telix were up 5.18 per cent on the market and were trading at $6.91 at 10:43 am AEST.